Conclusions: Accurate and informative labelling of hemp and hemp-derived CBD products is an important public health issue. FDA-regulated product labels are considered an essential tool for protecting consumers and enabling informed decision-making. Untruthful or unsubstantiated health-related claims, and unallowed Drug Claims, in marketing materials and on labels of CBD products may create harm by enticing consumers to forgo more evidence-based medical interventions. Furthermore, missing or inaccurate labelling of the amount of CBD, delta-9 tetrahydrocannabinol (THC), and potentially harmful contaminants such as pesticides, naturally-occurring yeast and mold or heavy metals may result in harm and/or lack of efficacy. Manufacturers of these products may reasonably be expected to understand and adhere to FDA regulations for labelling and marketing of food, dietary supplements and drugs, both over-the-counter (OTC) and prescription, even though FDA has interpreted federal law as excluding them from these categories. As manufacturers prepare for forthcoming regulations, a better understanding of the basic framework for FDA labelling and marketing regulations for food, dietary supplements and drugs is warranted.
Also see
- Heavy metal and phthalate contamination and labelling integrity in a large sample of commercially available cannabidiol (CBD) products
- FDA, FTC warn company marketing unapproved cannabidiol products
- FDA Says Most CBD Products May Not Be Safe, and Warns 15 Companies to Stop Selling Them
- What You Need to Know (And What We’re Working to Find Out) About Products Containing Cannabis or Cannabis-derived Compounds, Including CBD
- Dr Robert L Dupont's written Testimony to the FDA Regarding the Health Impacts of CBD
